Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | ACHE | P22303 | 2/20 | 0.65 |
| ▸ | MGAM | O43451 | 1/20 | 0.65 |
| ▸ | SI | P14410 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.65 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.48 |
| ▸ | HPGD | P15428 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decursin SCHEMBL29912722 | 1.00 | MAOA (1.00) | MAOAGAAACHEMGAMSI | |
| Decursin SCHEMBL14511556 | 1.00 | MAOA (1.00) | MAOAGAAACHEMGAMSI | |
| SCHEMBL4740846 | 0.88 | MAOA (0.79) | MAOAGAAACHEMGAMSI | |
| SCHEMBL14303567 | 0.88 | MAOA (0.79) | MAOAGAAACHEMGAMSI | |
| Decursinol Angelate SCHEMBL14310264 | 0.87 | MAOA (0.76) | MAOAGAAACHEMGAMSI | |
| Decursinol Angelate SCHEMBL4740622 | 0.87 | MAOA (0.76) | MAOAGAAACHEMGAMSI | |
| Decursinol Angelate SCHEMBL3901157 | 0.87 | MAOA (0.76) | MAOAGAAACHEMGAMSI | |
| Decursinol Angelate SCHEMBL3901154 | 0.87 | MAOA (0.76) | MAOAGAAACHEMGAMSI | |
| SCHEMBL14105695 | 0.84 | MAOA (0.73) | MAOAGAAACHEMGAMSI | |
| Dihydropyranocoumarin D2 SCHEMBL4714192 | 0.84 | MAOA (0.72) | MAOAGAAACHEMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1169034-A4 | DECURSINOL OR DERIVATIVE THEREOF AS ANALGESIC AGENT | SCIGENIC CO LTD (KR) | 2009-03-18 | — | — | EP | claimed |
| EP-1169034-A1 | DECURSINOL OR DERIVATIVE THEREOF AS ANALGESIC AGENT | Scigenic Co., Ltd. (KR) | 2002-01-09 | — | — | EP | claimed |
| WO-2001052841-A1 | DECURSINOL OR DERIVATIVE THEREOF AS ANALGESIC AGENT | SCIGENIC CO., LTD. (KR) | 2001-07-26 | — | — | WO | claimed |
| US-20230248791-A1 | METHODS FOR MANUFACTURING ANGELICA GIGAS NAKAI EXTRACT USING FERMENTATION BACTERIA | SOOY-K CO., LTD. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230248791-A1 | METHODS FOR MANUFACTURING ANGELICA GIGAS NAKAI EXTRACT USING FERMENTATION BACTERIA | SOOY-K CO., LTD. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230248791-A1 | METHODS FOR MANUFACTURING ANGELICA GIGAS NAKAI EXTRACT USING FERMENTATION BACTERIA | SOOY-K CO., LTD. (KR) | 2023-08-10 | — | — | US | disclosed |
| WO-2010064817-A2 | NOVEL COUMARIN-BASED COMPOUNDS, PREPARATION METHOD THEREOF, AND MULTIDRUG RESISTANCE INHIBITORY PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENTS | 한국생명공학연구원 (KR) | 2010-06-10 | — | — | WO | disclosed |
| EP-1169034-A4 | DECURSINOL OR DERIVATIVE THEREOF AS ANALGESIC AGENT | SCIGENIC CO LTD (KR) | 2009-03-18 | — | — | EP | disclosed |
| EP-1169034-A1 | DECURSINOL OR DERIVATIVE THEREOF AS ANALGESIC AGENT | Scigenic Co., Ltd. (KR) | 2002-01-09 | — | — | EP | disclosed |
| WO-2001052841-A1 | DECURSINOL OR DERIVATIVE THEREOF AS ANALGESIC AGENT | SCIGENIC CO., LTD. (KR) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248791-A1 | METHODS FOR MANUFACTURING ANGELICA GIGAS NAKAI EXTRACT USING FERMENTATION BACTERIA | CUTA, SHARPIN, GABRE | MAOA 293/4885GAA 525/4885ACHE 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.